<DOC>
	<DOCNO>NCT01774838</DOCNO>
	<brief_summary>To test vasoactive anti-inflammatory effect prasugrel patient acute coronary syndrome endothelial function -as surrogate parameter NO bioavailability- different marker inflammation , oxidative stress platelet activation assess patient unstable angina .</brief_summary>
	<brief_title>Vasoactive Anti-inflammatory Effects Prasugrel Acute Coronary Syndrome</brief_title>
	<detailed_description>Trial Objectives To test vasoactive anti-inflammatory effect prasugrel patient acute coronary syndrome , endothelial function -as surrogate parameter NO bioavailability- different marker inflammation , oxidative stress platelet activation assess patient unstable angina . Trial Design Single center , double blind , double-dummy , randomize , parallel trial . Endpoints Primary Endpoint Assessment endothelial function ( FMD ) via high-resolution ultrasound ( Sonoline G50 , 12 MHz linear array transducer , Siemens , Germany ) experience sonographer . Secondary Endpoints - Non-invasive assessment microvascular perfusion oxygen saturation laser Doppler perfusion image tissue spectrometry ( O2C , Lea Medizintechnik , Giessen , Germany ) - Determination leukocyte activity : plasma MPO level ( ELISA ) , plasma elastase level ( ELISA ) - Assessment platelet activity : plasma level sCD40 ligand ( ELISA ) , RANTES ( ELISA ) - Measurement different oxidative stress marker : hsCRP ( ELISA ) , CD40 ligand ( ELISA ) , carbonylated protein ( ELISA ) , urinary 8-iso-PGF2α ( gas chromatography mass spectrometry ) - Determination platelet-leukocyte aggregate fluorescent activate cell sorter ( FACS ) - Assessment platelet function ( PADA-test )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Acute coronary syndrome , unstable angina plan percutaneous coronary intervention Written inform consent Age &lt; 18 year ≥75 year Body weight &lt; 60 kg STEMI , NSTEMI Cardiogenic shock time randomization Refractory ventricular arrhythmia Congestive heart failure ( NYHA IV ) Increased risk bleed Active internal bleeding history hemorrhagic diathesis History TIA , ischemic hemorrhagic stroke Intracranial neoplasm , aneurysm arteriovenous malformation INR &gt; 1.5 screen Platelets &lt; 100,000/ml Anemia ( Hb &lt; 10 g/dl ) screen One dose thienopyridine 5 less PCI Oral anticoagulation safely discontinue duration study One dose thienopyridine 5 less PCI Treatment within last 30 investigational drug presently enrol another drug device study Women know pregnant , give birth within past 90 , breastfeed Concomitant medical illness opinion investigator associate reduce survival expected treatment period Known severe hepatic dysfunction Any condition associate poor treatment compliance , include alcoholism , mental illness , drug dependence Intolerance allergy aspirin , ticlopidine , clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>